1 usly irradiated bone metastases benefit from reirradiation.

2 isting organ dysfunction, for survival after reirradiation.

3 t prognostic factors for patients undergoing reirradiation.

4 for management and reviews recent results of reirradiation.

5 atients who underwent salvage surgery before reirradiation.

6                                   Concurrent reirradiation and chemotherapy is an alternative strateg

7 iation, recurrent tumor stage, tumor bulk at reirradiation, and reirradiation dose.

8             Data are accumulating to support reirradiation as a potentially curative approach for pat

9  electronic records of patients treated with reirradiation between January 1998 and 2008 were reviewe

10 gery before H-SRT, time to first recurrence, reirradiation dose, inclusion of chemotherapy with H-SRT

11 umor stage, tumor bulk at reirradiation, and reirradiation dose.

12                                              Reirradiation is a treatment option, although it is asso

13 necrosis of healthy brain tissue; therefore, reirradiation is usually not offered to patients with re

14 with both comorbidity and organ dysfunction, reirradiation largely serves as a palliative therapy.

15                       Patients responding to reirradiation of painful bone metastases experience supe

16 e/thrombosis/death) were comparable to prior reirradiation reports.

17                                        Focal reirradiation represents an option for select patients w

18                                       Before reirradiation, visual acuity ranged from 20/80 to counti

19  probability of death within 24 months after reirradiation was developed (concordance index = 0.75).